Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 1/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
| ▸ | KDM4A | O75164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27247829 | 0.89 | CACNA1B (0.44) | CACNA1HCACNA1BCACNA1CSMN1; SMN2PDE10A | |
| SCHEMBL27247213 | 0.88 | SCD (0.33) | SMN1; SMN2PDE10A | |
| SCHEMBL30920710 | 0.88 | CACNA1H (0.38) | CACNA1HCACNA1BCACNA1CSMN1; SMN2BCHE | |
| SCHEMBL30920680 | 0.87 | SMN1; SMN2 (0.40) | CACNA1HCACNA1BCACNA1CSMN1; SMN2BCHE | |
| SCHEMBL27247074 | 0.85 | IKBKB (0.33) | — | |
| SCHEMBL30920326 | 0.84 | CACNA1H (0.37) | CACNA1HCACNA1BCACNA1CSMN1; SMN2BCHE | |
| SCHEMBL30920547 | 0.84 | CACNA1H (0.37) | CACNA1HCACNA1BCACNA1CSMN1; SMN2BCHE | |
| SCHEMBL27247665 | 0.83 | EPHX2 (0.36) | — | |
| SCHEMBL30920217 | 0.83 | EPHX2 (0.36) | — | |
| SCHEMBL30920494 | 0.81 | CACNA1H (0.35) | CACNA1HCACNA1BCACNA1CSMN1; SMN2PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4601635-A2 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | Maze Therapeutics, Inc. (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20240199546-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | HERCULES CAPITAL, INC., AS AGENT | 2024-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199546-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | SLC6A19, SLC2A9, SLC6A3 | CACNA1H 1340/4885CACNA1B 559/4885CACNA1C 1103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.